公開日期 | 標題 | 作者 | 來源出版物 | WOS | 全文 |
2007 | Autologous cytokine-induced killer cells as post-transplant cellular immunotherapy | Arai, S.; Sheehan, K.; Moore, S.; Laport, G.; Johnston, L.; Lowsky, R.; Miklos, D.; Goldstein, K.; Wen-Kai Weng ; Shizuru, J.; Horning, S.; Negrin, R. | Blood | | |
2015 | Donor-Derived CIK Cell Infusion As Consolidative Therapy after Non-Myeloablative Allogeneic Transplant in Patients with Myeloid Neoplasms | Narayan, R.; Benjamin, J.; Laport, G.; Tian, L.; Tate, K.; Elder, L.; Galvez, L.; Armstrong, R.; Sheehan, K.; Lowsky, R.; Arai, S.; Johnston, L.; Miklos, D.; Muffly, L. S.; Rezvani, A. R.; Shizuru, J.; Wen-Kai Weng ; Strober, S.; Negrin, R.; Meyer, E. | Blood | | |
2016 | Long-term outcomes of high-dose melphalan and carmustine followed by autologous hematopoietic cell transplantation for multiple myeloma | Neppalli, A. K.; Shizuru, J.; Johnston, L. J.; Muffly, L. S.; Wen-Kai Weng ; Negrin, R.; Meyer, E.; Laport, G.; Lowsky, R.; Arai, S.; Miklos, D. B.; Rezvani, A. R. | Journal of Clinical Oncology | | |
2008 | Outcomes Following Allogeneic Hematopoietic Cell Transplantation (HCT) Using Non-Myeloablative Conditioning with Total Lymphoid Irradiation (TLI) and Anti-Thymocyte Globulin (ATG) Confirm a Low Incidence of Graft Versus Host Disease (GVHD) with Retained Anti-Tumor Activity | Kohrt, H.; Turnbull, B.; Laport, G.; Miklos, D.; Shizuru, J.; Johnston, L.; Arai, S.; Wen-Kai Weng ; Benjamin, J.; Blume, K.; Negrin, R.; Lavori, P.; Strober, S.; Lowsky, R. | Blood | | |
2015 | Phase I/II Clinical Trial of CpG-Activated Whole Cell Vaccine in Mantle Cell Lymphoma (MCL): Results in Safety and Efficacy from Planned Interim Analysis | Chu, M. P.; Brody, J.; Kohrt, H. E.; Frank, M. J.; Khodadoust, M.; Reddy, S.; Advani, R. H.; Gupta, N. K.; Laport, G.; Maeda, L. S.; Meyer, E.; Miklos, D. B.; Negrin, R.; Rezvani, A. R.; Wen-Kai Weng ; Sheehan, K.; Faham, M.; Czerwinski, D. K.; Okada, A.; Levy, R. | Blood | | |
2008 | Phase I/II Trial of a Novel Gemcitabine and Vinorelbine-Containing Conditioning Regimen in Autologous Hemotopoietic Cell Transplantation for High-Risk Recurrent and Refractory Hodgkin Lymphoma | Arai, S.; Letsinger, R.; Johnston, L.; Laport, G.; Lowsky, R.; Miklos, D.; Shizuru, J.; Wen-Kai Weng ; Wong, R.; Lavori, P.; Blume, K.; Negrin, R.; Horning, S. | Blood | | |
2008 | Prophylactic Rituximab after Reduced Intensity Conditioning Transplantation Results in Low Chronic Gvhd | Arai, S.; Sahaf, B.; Jones, C.; Zhender, J.; Lowsky, R.; Strober, S.; Shizuru, J.; Negrin, R.; Johnston, L.; Laport, G.; Schaenman, J.; Brown, J.; Wen-Kai Weng ; Letsinger, R.; Wong, R.; Lavori, P.; Miklos, D. | Blood | | |
2019 | Transplantation of donor grafts with defined ratio of conventional and regulatory T cells in HLA-matched recipients | Meyer, E. H.; Laport, G.; Xie, B. J.; MacDonald, K.; Heydari, K.; Sahaf, B.; Tang, S. W.; Baker, J.; Armstrong, R.; Tate, K.; Tadisco, C.; Arai, S.; Johnston, L.; Lowsky, R.; Muffly, L.; Rezvani, A. R.; Shizuru, J.; Wen-Kai Weng ; Sheehan, K.; Miklos, D.; Negrin, R. S. | Jci Insight | | |